Quantum Genomics (Alternext - FR0011648971 - ALQGC), a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, will be participating at the 10th edition of the European Smallcap Event, a conference dedicated to meetings between European listed companies and institutional investors, to be held in Paris on April 27 & 28, 2015.
On that occasion, Lionel Ségard, Chairman and Chief Executive Officer of Quantum Genomics, and Marc Karako, Chief Financial Officer, will comment on the 2014 annual results and the developments in its four research programmes: the launch in the 1st quarter of 2015, of Phase IIa clinical trials of its drug candidate QGC001 to combat high blood pressure, QGC011 for high blood pressure in combination with other drugs, QGC006 as the best-in-class monotherapy for high blood pressure, and QGC101 for the prevention and treatment of heart failure.
Next meeting: April 22, 2015, after close of trading, the 2014 annual financial report will be available, plus update on business activity in 1st quarter 2015.
Quantum Genomics is a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, especially high blood pressure and heart failure.
Quantum Genomics is developing a new therapeutic approach based on BAPAI (Brain Aminopeptidase A Inhibition). This is the result of more than 20 years of academic research in the laboratories of the Collège de France, INSERM, CNRS and the University of Paris Descartes.
Quantum Genomics is listed on the Alternext market in Paris (ISIN code FR0011648971, Ticker ALQGC).
Chairman & Chief Executive Officer
+33 1 85 34 77 77
CFO – Investor Relations
+33 1 85 34 77 75
ACTUS finance & communication
+33 1 53 67 36 73
Powered by Actusnews Wire (press release services) ©